Skip to Main Content

WASHINGTON — The bipartisan duo behind a 2016 law that poured billions into medical research want to repeat their success. But so far, the pharmaceutical industry that helped push the first version across the finish line isn’t nearly so eager to lend the new effort much support.

The 21st Century Cures Act has been lauded since its passage for both the funding it included and its revamp of the regulatory landscape for medical breakthroughs. The bill’s architects, Reps. Diana DeGette (D-Colo.) and Fred Upton (R-Mich.) have spent the last four months pushing a sequel, dubbed Cures 2.0, on a mini speaking tour around Washington.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!